Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC

On May 11, 2026, Vector Science & Therapeutics announced a three-year development and manufacturing agreement with MPP Group LLC. The deal provides immediate access to an FDA-registered, cGMP-compliant facility in Mequon, Wisconsin, for formulation, analytical testing, and aseptic manufacturing of peptide-based products. The partnership targets 22 novel, shelf-stable peptide formulations (up to 24 months), including 14 peptides recently removed from the FDA Category 2 list, making them eligible for physician-supervised compounding. Critically, Vector avoids duplicating manufacturing infrastructure, saving an estimated $6 million in capital expenditures, while retaining full ownership of dedicated equipment. Work is scheduled to begin in May 2026. The agreement is positioned as the foundational step toward commercializing Vector’s proprietary transdermal delivery technology and addressing the $80.8 billion peptide market.

The manufacturing agreement materially derisks Vector’s near-term development pathway and significantly changes the company’s operational profile from a preclinical concept to a tangible, near-commercial-stage peptide developer. Prior to this news, the company had completed a reverse takeover on April 24, 2026, raising only C$2.3M, and filed a provisional patent for a cancer-focused intratumoral catheter—an early preclinical asset with no data. The MPP deal was entirely unanticipated in the public narrative; the RTO disclosures and patent filing made no mention of an imminent manufacturing partnership or a 22-peptide pipeline. The announced savings of $6M exceed the entire concurrent financing, effectively giving Vector a manufacturing backbone it could not have self-funded. While the agreement is not an offtake, licensing, or FDA approval, it moves the company from “science project” to “supply chain ready,” a critical leap for a micro-cap biotech. The peptide menu includes commercial favorites (BCP-157, PT-141, Sermorelin, etc.) that target large wellness and anti-aging markets, adding near-term revenue potential. The news therefore qualifies as genuinely new and market-moving—worthy of a Material - Positive designation.

Vector Science and Therapeutics Corp. (formerly OpenSesame Acquisition Corp.) listed on the TSXV on April 28, 2026, via a reverse takeover. Its flagship initiative centers on developing proprietary drug-delivery platforms (including a transdermal system and an intratumoral catheter) combined with peptide therapeutics. The intratumoral catheter platform, for which a provisional patent was filed May 1, 2026, targets pancreatic cancer using three electrical modalities, but remains in preclinical discovery with no data. In parallel, the company is building a diversified pipeline of 22 peptides (initially focused on compounding-eligible compounds) aimed at large wellness, longevity, and sexual health markets. The company promotes its leadership’s experience in biomechanical devices and commercialization.